Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc. is a biopharmaceutical company that specialises in developing solutions for rare neuromuscular diseases. The company is a leader in the field of precision genetic medicine, with its core activities focused in gene therapy, gene editing, and RNA technologies. Sarepta Therapeutics was founded in 1980 under its original name of AntiVirals, Inc. It changed its areas of specialism, and its name, first to AVI BioPharma in 1997, before rebranding as Sarepta Therapeutics, Inc. in 2012. Operating globally, the company employs over 850 people and has offices in France, Germany, Ireland, Switzerland, and the UK, with its headquarters in Cambridge, Massachusetts. The genetic diseases that Sarepta Therapeutics focuses on include Duchenne muscular dystrophy, limb-girdle muscular dystrophy, mucopolysaccharidosis IIIA, and Charcot-Marie-Tooth disease. Sarepta Therapeutics has over 40 therapies in various stages of development. Current products include Exondys 51, Vyondys 53, and Amondys 45. Sarepta Therapeutics, Inc. trades using the ticker SRPT on the NASDAQ. The company partners with a range of companies, including AavantiBio, Inc., Dyno Therapeutics, Lysogene, and Roche. It also works closely with several universities, including Columbia University, Harvard University, and the University of Western Australia. Add SRPT stock to your eToro watchlist and stay up to date with all the latest news and stock value changes.